65,437 trials
Major Depressive Disorder
Primary: The Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -9.2; -7.2 units on a scale
Cataract
Primary: Percentage of Subjects With AC Cell Count of Zero on Day 7 — 3; 2 Participants
Cancer
Primary: Numerical Rating Scale (NRS) — 3.91; 3.87 scores on a scale
Breast Cancer
Primary: Percentage of Participants With Objective Response (OR) by Centrally Assessed Breast Magnetic Resonance Imaging (MRI) Via Modified Response Evaluation Criteria in Solid…
Neuromuscular Blockade
Primary: IL-6 — 84; 70.14 pg / ml
AIDS
Primary: Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline — 1.0; 1.5; 1.3 RNA copies/mL
Signs and Symptoms
Primary: Sensitivity — 53 percentage of positive scans
Major Depressive Disorder (MDD) · History of Childhood Sexual Abuse (CSA)
Primary: Dopamine Active Transporter Binding Potential — 3.191; 3.161; 3.175; 3.216 Ratio
Acute Pain
Primary: Number of Patients With Satisfactory Pain Management at 60 Minutes — 112; 113 Participants
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
Vaccine Efficacy
Primary: Humoral Immunity to TBE (Tick-borne Encephalitis) Vaccine — 574.8; 612.0 Geometric mean titers
Duchenne Muscular Dystrophy
Primary: Bayley III Gross Motor Scaled Score (Change From Baseline to 12 Month) — 4.8 units on a scale
Amyotrophic Lateral Sclerosis (ALS)
Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) — -1.20; -0.94 units on a scale — p=0.07
Healthy Volunteers
Primary: The Effects of CYP2B6 Genetic Variants on Ketamine Metabolism and Clearance by CYP2B6*6 Hetero or Homozygote Genotype. — 29; 21; 26; 19 ng/ml*hr — p=<0.05
Secondary Hyperparathyroidism, Chronic Kidney Disease
Primary: Number of Participants With Adverse Events — 9; 10; 1; 2 Participants